| Range: | 1.1-7.33 | Vol Avg: | 126414 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 1.27 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Dec 04 2017 | Empoloyees: | 2 | ||
| CUSIP: | 089482103 | CIK: | 0001719406 | ISIN: | US6294441000 | Country: | US |
| CEO: | Dr. Jonathan C. Javitt M.D., M.P.H. | Website: | https://www.nrxpharma.com | ||||
NRXP 1.27 Stock Price NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Stock Details
Positive 0.43
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024
WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (...
prnewswire.com·Tue Nov 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow